Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
896 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07227311 | A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) | recruiting | Phase 2 | 200 | GlaxoSmithKlineINDUSTRY | 8 | Aug 25, 2026 | clinicaltrials |
| NCT05775159 | Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer | active not recruiting | Phase 2 | 294 | AstraZenecaINDUSTRY | 9 | Aug 24, 2026 |
| clinicaltrials |
| NCT05951179 | Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer(ADVANCED-2) | recruiting | Phase 2 | 131 | Protara TherapeuticsINDUSTRY | 7 | Aug 24, 2026 | clinicaltrials |
| NCT07220616 | A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies | recruiting | Phase 1 / Phase 2 | 420 | Daiichi SankyoINDUSTRY | 4 | Aug 24, 2026 | clinicaltrials |
| NCT03940703 | A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) | completed | Phase 2 | 140 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 17 | Aug 21, 2026 | clinicaltrials |
| NCT04579380 | Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations | active not recruiting | Phase 2 | 217 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 8 | Aug 21, 2026 | clinicaltrials |
| NCT05458297 | A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) | active not recruiting | Phase 2 | 189 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Aug 21, 2026 | clinicaltrials |
| NCT05797168 | Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors(FONTANA) | recruiting | Phase 1 / Phase 2 | 602 | AstraZenecaINDUSTRY | 12 | Aug 21, 2026 | clinicaltrials |
| NCT07209111 | A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)(KANDLELIT-014) | recruiting | Phase 2 | 150 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Aug 21, 2026 | clinicaltrials |
| NCT04557449 | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors(CDK4i) | active not recruiting | Phase 2 | 362 | PfizerINDUSTRY | 8 | Aug 20, 2026 | clinicaltrials |
| NCT07129993 | Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma | recruiting | Phase 2 / Phase 3 | 630 | Daiichi SankyoINDUSTRY | 7 | Aug 20, 2026 | clinicaltrials |
| NCT04683250 | Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities(MARGARET) | recruiting | Phase 1 / Phase 2 | 244 | Taiho Pharmaceutical Co., Ltd.INDUSTRY | 4 | Aug 19, 2026 | clinicaltrials |
| NCT05714839 | A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments(DynaMMic-1) | recruiting | Phase 1 / Phase 2 | 123 | GlaxoSmithKlineINDUSTRY | 13 | Aug 19, 2026 | clinicaltrials |
| NCT06084884 | A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma(ATHENA) | active not recruiting | Phase 1 / Phase 2 | 94 | AstraZenecaINDUSTRY | 3 | Aug 19, 2026 | clinicaltrials |
| NCT06106945 | AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 226 | AstraZenecaINDUSTRY | 9 | Aug 19, 2026 | clinicaltrials |
| NCT06137118 | AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia(SYRUS) | recruiting | Phase 1 / Phase 2 | 255 | AstraZenecaINDUSTRY | 13 | Aug 19, 2026 | clinicaltrials |
| NCT07115043 | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 120 | AstraZenecaINDUSTRY | 4 | Aug 19, 2026 | clinicaltrials |
| NCT04895709 | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 1,109 | Bristol-Myers SquibbINDUSTRY | 8 | Aug 17, 2026 | clinicaltrials |
| NCT06745323 | A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC(DeLLphi-309) | active not recruiting | Phase 2 | 252 | AmgenINDUSTRY | 16 | Aug 17, 2026 | clinicaltrials |
| NCT03742895 | Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002) | active not recruiting | Phase 2 | 329 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Aug 14, 2026 | clinicaltrials |
| NCT05853575 | Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) | active not recruiting | Phase 2 | 200 | Mirati Therapeutics Inc.INDUSTRY | 18 | Aug 14, 2026 | clinicaltrials |
| NCT01784068 | Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients(ENESTfreedom) | completed | Phase 2 | 215 | Novartis PharmaceuticalsINDUSTRY | 19 | Aug 13, 2026 | clinicaltrials |
| NCT05309668 | Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN(SPRINKLE) | active not recruiting | Phase 1 / Phase 2 | 36 | AstraZenecaINDUSTRY | 7 | Aug 13, 2026 | clinicaltrials |
| NCT06795022 | First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours(RHEA-1) | recruiting | Phase 1 / Phase 2 | 304 | AstraZenecaINDUSTRY | 7 | Aug 13, 2026 | clinicaltrials |
| NCT01698905 | Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)(ENESTop) | completed | Phase 2 | 163 | Novartis PharmaceuticalsINDUSTRY | 18 | Aug 12, 2026 | clinicaltrials |
| NCT06526819 | SMP-3124LP in Adults With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 120 | Sumitomo Pharma America, Inc.INDUSTRY | 2 | Aug 12, 2026 | clinicaltrials |
| NCT07160725 | A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 540 | Bristol-Myers SquibbINDUSTRY | 5 | Aug 11, 2026 | clinicaltrials |
| NCT06926868 | A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | recruiting | Phase 2 / Phase 3 | 600 | Bristol-Myers SquibbINDUSTRY | 28 | Aug 10, 2026 | clinicaltrials |
| NCT07336446 | A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs(ANDROMEDA) | recruiting | Phase 1 / Phase 2 | 300 | AstraZenecaINDUSTRY | 8 | Aug 10, 2026 | clinicaltrials |
| NCT03706365 | A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer(CYCLONE 2) | active not recruiting | Phase 2 / Phase 3 | 393 | Eli Lilly and CompanyINDUSTRY | 11 | Aug 7, 2026 | clinicaltrials |
| NCT04145349 | CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor | completed | Phase 1 / Phase 2 | 30 | Eli Lilly and CompanyINDUSTRY | 7 | Aug 7, 2026 | clinicaltrials |
| NCT05999994 | A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer(CAMPFIRE) | recruiting | Phase 2 | 105 | Eli Lilly and CompanyINDUSTRY | 10 | Aug 7, 2026 | clinicaltrials |
| NCT07750353 | A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic Carcinomas(XANTHOS) | not yet recruiting | Phase 2 | 35 | National Cancer Center, JapanOTHER_GOV | 1 | Aug 6, 2026 | clinicaltrials |
| NCT01081951 | Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer | active not recruiting | Phase 2 | 162 | AstraZenecaINDUSTRY | 13 | Aug 5, 2026 | clinicaltrials |
| NCT02519348 | A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma | active not recruiting | Phase 2 | 433 | MedImmune LLCINDUSTRY | 9 | Aug 5, 2026 | clinicaltrials |
| NCT06330064 | A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) | recruiting | Phase 1 / Phase 2 | 680 | Daiichi SankyoINDUSTRY | 18 | Aug 5, 2026 | clinicaltrials |
| NCT06706076 | A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations(SOLARA) | recruiting | Phase 1 / Phase 2 | 675 | BlossomHill TherapeuticsINDUSTRY | 9 | Aug 5, 2026 | clinicaltrials |
| NCT06940791 | Tirabrutinib Maintenance Versus Placebo in Patients With Primary CNS Lymphoma in Complete Remission (JCOG2104)(TIMELY-pII) | recruiting | Phase 2 | 92 | Kyorin UniversityOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07699939 | Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma(PLATANUS) | recruiting | Phase 2 | 136 | National Cancer Center, JapanOTHER_GOV | 2 | Aug 5, 2026 | clinicaltrials |
| NCT05579366 | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)(RAINFOL-01) | recruiting | Phase 1 / Phase 2 | 884 | GenmabINDUSTRY | 3 | Aug 4, 2026 | clinicaltrials |
| NCT06622941 | Study to ONO-4538 in Patients With Rhabdoid Tumor | recruiting | Phase 2 | 23 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06885034 | A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201) | recruiting | Phase 1 / Phase 2 | 451 | GlaxoSmithKlineINDUSTRY | 19 | Aug 3, 2026 | clinicaltrials |
| NCT03888105 | A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies(ELM-2) | active not recruiting | Phase 2 | 515 | Regeneron PharmaceuticalsINDUSTRY | 14 | Jul 31, 2026 | clinicaltrials |
| NCT05265273 | A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis | recruiting | Phase 2 / Phase 3 | 12 | Janssen Research & Development, LLCINDUSTRY | 4 | Jul 31, 2026 | clinicaltrials |
| NCT05669989 | International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab | enrolling by invitation | Phase 2 | 70 | SanofiINDUSTRY | 17 | Jul 31, 2026 | clinicaltrials |
| NCT06921928 | Study for AZD4360 in Participants With Advanced Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 31 | AstraZenecaINDUSTRY | 5 | Jul 31, 2026 | clinicaltrials |
| NCT06710132 | Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) | active not recruiting | Phase 1 / Phase 2 | 184 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 10 | Jul 30, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials